Efficacy
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP)
A total of 726 adult patients hospitalized with HABP/VABP were enrolled in a multinational, double-blind study (NCT02070757) comparing ZERBAXA 3 g (ceftolozane 2 g and tazobactam 1 g) intravenously every 8 hours to meropenem (1 g intravenously every 8 hours) for 8 to 14 days of therapy. All patients had to be intubated and on mechanical ventilation at randomization.
Efficacy was assessed based on all-cause mortality at Day 28 and clinical cure, defined as complete resolution or significant improvement in signs and symptoms of the index infection at the test-of-cure (TOC) visit which occurred 7 to 14 days after the end of treatment. The analysis population was the intent-to-treat (ITT) population, which included all randomized patients.
Following a diagnosis of HABP/VABP and prior to receipt of first dose of study drug, if required, patients could have received up to a maximum of 24 hours of active non-study antibacterial drug therapy in the 72 hours preceding the first dose of study drug. Patients who had failed prior antibacterial drug therapy for the current episode of HABP/VABP could be enrolled if the baseline lower respiratory tract (LRT) culture showed growth of a Gram-negative pathogen while the patient was on the antibacterial therapy and all other eligibility criteria were met. Empiric therapy at baseline with linezolid or other approved therapy for Gram-positive coverage was required in all patients pending baseline LRT culture results. Adjunctive Gram-negative therapy was optional and allowed for a maximum of 72 hours in centers with a prevalence of meropenem-resistant P. aeruginosa more than 15%.
Of the 726 patients in the ITT population, the median age was 62 years and 44% of the population was 65 years of age and older, with 22% of the population 75 years of age and older. The majority of patients were white (83%), male (71%) and were from Eastern Europe (64%). The median APACHE II score was 17 and 33% of subjects had a baseline APACHE II score of greater than or equal to 20. All subjects were on mechanical ventilation and 519 (71%) had VABP. At randomization, 92% of subjects were in the ICU, 77% had been hospitalized for 5 days or longer, and 49% were ventilated for 5 days or longer. A total of 258 of 726 (36%) patients had CrCl less than 80 mL/min at baseline; among these, 99 (14%) had CrCl less than 50 mL/min. Patients with end-stage renal disease (CrCl less than 15 mL/min) were excluded from the trial. Approximately 13% of subjects were failing their current antibacterial drug therapy for HABP/VABP, and bacteremia was present at baseline in 15% of patients. Key comorbidities included diabetes mellitus, congestive heart failure, and chronic obstructive pulmonary disease at rates of 22%, 16%, and 12%, respectively. In both treatment groups, most subjects (63.1%) received between 8 and 14 days of study therapy as specified in the protocol.
The table below presents the results for Day 28 all-cause mortality and clinical cure at the TOC visit overall and by ventilated HABP and VABP.
Day 28 All-cause Mortality and Clinical Cure Rates at TOC from a Phase 3 Study of Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) (ITT Population)
Endpoint | ZERBAXA n/N (%) | Meropenem n/N (%) | Treatment Difference (95% CI)a |
---|---|---|---|
Day 28 All-cause Mortality | 87/362 (24.0) | 92/364 (25.3) | 1.1 (-5.13, 7.39) |
VABP | 63/263 (24.0) | 52/256 (20.3) | -3.6 (-10.74, 3.52) |
Ventilated HABP | 24/99 (24.2) | 40/108 (37.0) | 12.8 (0.18, 24.75) |
Clinical Cure at TOC Visit | 197/362 (54.4) | 194/364 (53.3) | 1.1 (-6.17, 8.29) |
VABP | 147/263 (55.9) | 146/256 (57.0) | -1.1 (-9.59, 7.35) |
Ventilated HABP | 50/99 (50.5) | 48/108 (44.4) | 6.1 (-7.44, 19.27) |
(a) The CI for overall treatment difference was based on the stratified Newcombe method with minimum risk weights. The CI for treatment difference of each primary diagnosis was based on the unstratified Newcombe method.
In the ITT population, Day 28 all-cause mortality and clinical cure rates in patients with CrCl greater than or equal to 150 mg/mL were similar between ZERBAXA and meropenem. In patients with bacteremia at baseline, Day 28 all-cause mortality rates were 23/64 (35.9%) for ZERBAXA-treated patients and 13/41 (31.7%) for meropenem-treated patients; clinical cure rates were 30/64 (46.9%) and 15/41 (36.6%), respectively.
Per pathogen Day 28 all-cause mortality and clinical cure at TOC were assessed in the microbiologic intention to treat population (mITT), which consisted of all randomized subjects who had a baseline lower respiratory tract (LRT) pathogen that was susceptible to both study treatments. In the mITT population, Klebsiella pneumoniae (113/425, 26.6%) and Pseudomonas aeruginosa (103/425, 24.2%) were the most prevalent pathogens isolated from baseline LRT cultures.
Day 28 all-cause mortality and clinical cure rates at TOC by pathogen in the mITT population are presented in the table below. In the mITT population, clinical cure rates in patients with a Gram-negative pathogen at baseline were 139/215 (64.7%) for ZERBAXA and 115/204 (56.4%) for meropenem, respectively.
Day 28 All-cause Mortality and Clinical Cure Rates at TOC by Baseline Pathogen from a Phase 3 Study of Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) (mITT population)
Baseline Pathogen Category
Baseline Pathogen |
Day 28 All-cause Mortality | Clinical Cure at TOC | ||
---|---|---|---|---|
ZERBAXA n/N (%) | Meropenem n/N (%) | ZERBAXA n/N (%) | Meropenem n/N (%) | |
Pseudomonas aeruginosa | 12/47 (25.5) | 10/56 (17.9) | 29/47 (61.7) | 34/56 (60.7) |
Enterobacteriaceae | 27/161 (16.8) | 42/157 (26.8) | 103/161 (64.0) | 87/157 (55.4) |
Enterobacter cloacae | 2/15 (13.3) | 8/14 (57.1) | 8/15 (53.3) | 4/14 (28.6) |
Escherichia coli | 10/50 (20.0) | 11/42 (26.2) | 32/50 (64.0) | 26/42 (61.9) |
Klebsiella oxytoca | 3/14 (21.4) | 3/12 (25.0) | 9/14 (64.3) | 7/12 (58.3) |
Klebsiella pneumoniae | 7/51 (13.7) | 13/62 (21.0) | 34/51 (66.7) | 39/62 (62.9) |
Proteus mirabilis | 5/22 (22.7) | 5/18 (27.8) | 13/22 (59.1) | 11/18 (61.1) |
Serratia marcescens | 3/14 (21.4) | 1/12 (8.3) | 8/14 (57.1) | 7/12 (58.3) |
Haemophilus | 0/20 (0) | 2/15 (13.3) | 17/20 (85.0) | 8/15 (53.3) |
In a subset of Enterobacteriaceae isolates from both arms of the trial that met pre-specified criteria for beta-lactam susceptibility, genotypic testing identified certain ESBL groups (e.g., TEM, SHV, CTX-M, OXA) in 101/425 (23.8%). Day 28 all-cause mortality and clinical cure rates in this subset were similar to the overall trial results.